GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Winddown Corp (OTCPK:PLXPQ) » Definitions » Piotroski F-Score

PLx Pharma Winddown (PLx Pharma Winddown) Piotroski F-Score : 0 (As of May. 02, 2024)


View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma Winddown Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PLx Pharma Winddown has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for PLx Pharma Winddown's Piotroski F-Score or its related term are showing as below:


PLx Pharma Winddown Piotroski F-Score Historical Data

The historical data trend for PLx Pharma Winddown's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PLx Pharma Winddown Piotroski F-Score Chart

PLx Pharma Winddown Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 3.00 3.00 4.00 3.00

PLx Pharma Winddown Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 3.00 4.00 3.00 2.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep22) TTM:Last Year (Sep21) TTM:
Net Income was 3.562 + -10.785 + -11.858 + -8.497 = $-27.58 Mil.
Cash Flow from Operations was -13.361 + -16.893 + -18.099 + -10.982 = $-59.34 Mil.
Revenue was 1.592 + 2.083 + 0.483 + 0.386 = $4.54 Mil.
Gross Profit was 0.7 + 0.914 + -0.337 + -1.074 = $0.20 Mil.
Average Total Assets from the begining of this year (Sep21)
to the end of this year (Sep22) was
(91.836 + 76.642 + 60.858 + 44.54 + 33.224) / 5 = $61.42 Mil.
Total Assets at the begining of this year (Sep21) was $91.84 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $30.22 Mil.
Total Current Liabilities was $6.31 Mil.
Net Income was -7.982 + -11.54 + -16.505 + -21.642 = $-57.67 Mil.

Revenue was 0 + 0 + 0 + 6.616 = $6.62 Mil.
Gross Profit was 0 + 0 + 0 + 2.703 = $2.70 Mil.
Average Total Assets from the begining of last year (Sep20)
to the end of last year (Sep21) was
(13.351 + 26.617 + 88.321 + 85.309 + 91.836) / 5 = $61.0868 Mil.
Total Assets at the begining of last year (Sep20) was $13.35 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $88.61 Mil.
Total Current Liabilities was $7.41 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PLx Pharma Winddown's current Net Income (TTM) was -27.58. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PLx Pharma Winddown's current Cash Flow from Operations (TTM) was -59.34. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep21)
=-27.578/91.836
=-0.30029618

ROA (Last Year)=Net Income/Total Assets (Sep20)
=-57.669/13.351
=-4.31945173

PLx Pharma Winddown's return on assets of this year was -0.30029618. PLx Pharma Winddown's return on assets of last year was -4.31945173. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

PLx Pharma Winddown's current Net Income (TTM) was -27.58. PLx Pharma Winddown's current Cash Flow from Operations (TTM) was -59.34. ==> -59.34 <= -27.58 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep21 to Sep22
=0/61.42
=0

Gearing (Last Year: Sep21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep20 to Sep21
=0/61.0868
=0

PLx Pharma Winddown's gearing of this year was 0. PLx Pharma Winddown's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep22)=Total Current Assets/Total Current Liabilities
=30.221/6.312
=4.78786439

Current Ratio (Last Year: Sep21)=Total Current Assets/Total Current Liabilities
=88.614/7.405
=11.9667792

PLx Pharma Winddown's current ratio of this year was 4.78786439. PLx Pharma Winddown's current ratio of last year was 11.9667792. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

PLx Pharma Winddown's number of shares in issue this year was 28.603. PLx Pharma Winddown's number of shares in issue last year was 26.912. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.203/4.544
=0.0446743

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2.703/6.616
=0.40855502

PLx Pharma Winddown's gross margin of this year was 0.0446743. PLx Pharma Winddown's gross margin of last year was 0.40855502. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep21)
=4.544/91.836
=0.04947951

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep20)
=6.616/13.351
=0.4955434

PLx Pharma Winddown's asset turnover of this year was 0.04947951. PLx Pharma Winddown's asset turnover of last year was 0.4955434. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+1+0+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PLx Pharma Winddown has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

PLx Pharma Winddown  (OTCPK:PLXPQ) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


PLx Pharma Winddown Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of PLx Pharma Winddown's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


PLx Pharma Winddown (PLx Pharma Winddown) Business Description

Traded in Other Exchanges
N/A
Address
8 The Green, Suite 11895, Dover, DE, USA, 19901
PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.
Executives
Rita M O'connor officer: Chief Financial Officer 4 OAK PARKWAY, SPARTA NJ 07871
Natasha Giordano director, officer: Chief Executive Officer 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Michael J Valentino director, officer: Executive Chairman 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
John Hadden director 1375 S FORT HARRISON AVE, CLEARWATER FL 33756
Robert D. Hardie 10 percent owner 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Molly G. Hardie 10 percent owner 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Level One Partners, Llc 10 percent owner 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Kirk K Calhoun director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Gary S. Balkema director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Robert Casale director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Anthony Bartsh director C/O PARK WEST ASSET MANAGEMENT, LLC, 900 LARKSPUR CIRCLE, SUITE 165, LARKSPUR CA 94939
Park West Asset Management Llc 10 percent owner 1 LETTERMAN DRIVE, SUITE C5-900, SAN FRANCISCO CA 94129
Efthymios Deliargyris officer: Chief Medical Officer C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054
Gary L Mossman officer: Chief Operating Officer 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
David Emerson Jorden officer: Acting Chief Financial Officer 2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS TX 77381

PLx Pharma Winddown (PLx Pharma Winddown) Headlines